PortfoliosLab logoPortfoliosLab logo
ATAI vs. ATYR
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ATAI vs. ATYR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and aTyr Pharma, Inc. (ATYR). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ATAI vs. ATYR - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ATAI
Atai Life Sciences N.V.
-13.45%207.52%-5.67%-46.99%-65.14%-60.77%
ATYR
aTyr Pharma, Inc.
-0.40%-78.37%156.74%-35.62%-70.68%66.00%

Fundamentals

EPS

ATAI:

-$2.72

ATYR:

-$0.80

PS Ratio

ATAI:

210.21

ATYR:

384.40

Total Revenue (TTM)

ATAI:

$4.09M

ATYR:

$190.00K

Gross Profit (TTM)

ATAI:

$3.08M

ATYR:

-$34.17M

EBITDA (TTM)

ATAI:

-$113.05M

ATYR:

-$76.54M

Returns By Period

In the year-to-date period, ATAI achieves a -13.45% return, which is significantly lower than ATYR's -0.40% return.


ATAI

1D
4.12%
1M
-2.48%
YTD
-13.45%
6M
-33.08%
1Y
160.29%
3Y*
25.06%
5Y*
10Y*

ATYR

1D
6.72%
1M
-18.73%
YTD
-0.40%
6M
8.12%
1Y
-74.17%
3Y*
-28.12%
5Y*
-29.78%
10Y*
-34.46%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ATAI vs. ATYR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI
ATAI Risk / Return Rank: 8585
Overall Rank
ATAI Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
ATAI Sortino Ratio Rank: 8888
Sortino Ratio Rank
ATAI Omega Ratio Rank: 8484
Omega Ratio Rank
ATAI Calmar Ratio Rank: 8686
Calmar Ratio Rank
ATAI Martin Ratio Rank: 7979
Martin Ratio Rank

ATYR
ATYR Risk / Return Rank: 2121
Overall Rank
ATYR Sharpe Ratio Rank: 1515
Sharpe Ratio Rank
ATYR Sortino Ratio Rank: 2929
Sortino Ratio Rank
ATYR Omega Ratio Rank: 2929
Omega Ratio Rank
ATYR Calmar Ratio Rank: 1111
Calmar Ratio Rank
ATYR Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATAI vs. ATYR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and aTyr Pharma, Inc. (ATYR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ATAIATYRDifference

Sharpe ratio

Return per unit of total volatility

1.89

-0.61

+2.50

Sortino ratio

Return per unit of downside risk

2.65

-0.03

+2.68

Omega ratio

Gain probability vs. loss probability

1.32

1.00

+0.33

Calmar ratio

Return relative to maximum drawdown

2.93

-0.83

+3.76

Martin ratio

Return relative to average drawdown

5.49

-1.16

+6.64

ATAI vs. ATYR - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 1.89, which is higher than the ATYR Sharpe Ratio of -0.61. The chart below compares the historical Sharpe Ratios of ATAI and ATYR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ATAIATYRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.89

-0.61

+2.50

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.36

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.40

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.36

-0.46

+0.11

Correlation

The correlation between ATAI and ATYR is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ATAI vs. ATYR - Dividend Comparison

Neither ATAI nor ATYR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ATAI vs. ATYR - Drawdown Comparison

The maximum ATAI drawdown since its inception was -94.77%, smaller than the maximum ATYR drawdown of -99.83%. Use the drawdown chart below to compare losses from any high point for ATAI and ATYR.


Loading graphics...

Drawdown Indicators


ATAIATYRDifference

Max Drawdown

Largest peak-to-trough decline

-94.77%

-99.83%

+5.06%

Max Drawdown (1Y)

Largest decline over 1 year

-48.06%

-90.15%

+42.09%

Max Drawdown (5Y)

Largest decline over 5 years

-94.78%

Max Drawdown (10Y)

Largest decline over 10 years

-99.26%

Current Drawdown

Current decline from peak

-82.20%

-99.80%

+17.60%

Average Drawdown

Average peak-to-trough decline

-79.80%

-93.07%

+13.27%

Ulcer Index

Depth and duration of drawdowns from previous peaks

25.66%

64.91%

-39.25%

Volatility

ATAI vs. ATYR - Volatility Comparison

Atai Life Sciences N.V. (ATAI) and aTyr Pharma, Inc. (ATYR) have volatilities of 20.69% and 21.76%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ATAIATYRDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.69%

21.76%

-1.07%

Volatility (6M)

Calculated over the trailing 6-month period

53.14%

61.00%

-7.86%

Volatility (1Y)

Calculated over the trailing 1-year period

85.60%

121.55%

-35.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.11%

83.77%

+0.34%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.11%

85.40%

-1.29%

Financials

ATAI vs. ATYR - Financials Comparison

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and aTyr Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
1.07M
190.00K
(ATAI) Total Revenue
(ATYR) Total Revenue
Values in USD except per share items